CAMMA-2

A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma (CAMMA 2)

What's the purpose of the trial?

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with relapsed or refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Trial status

Accepting patients

Phase
Phase 1/2
Enrollment
90
Last Updated
1 month ago
Am I Eligible

Participating Centers

There are 11 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Cevostamab is a bispecific T-cell engager antibody that targets both FCRH5 found on cancer cells and CD3 antigen found on T lymphocytes.
  • Tocilizumab is an immunosuppressive drug that is used to treat several different indications.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Patients with Prior CAR-T

Accepting patients

Patients with Prior CAR-T

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.